IDEXX Laboratories, Inc. $IDXX Shares Bought by Cerity Partners LLC

Cerity Partners LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 21,170 shares of the company’s stock after buying an additional 2,540 shares during the quarter. Cerity Partners LLC’s holdings in IDEXX Laboratories were worth $11,355,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. STF Management LP lifted its stake in shares of IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after acquiring an additional 16 shares during the period. Clearstead Trust LLC raised its holdings in IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares during the period. Stratos Wealth Partners LTD. boosted its holdings in shares of IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after buying an additional 18 shares during the period. Red Spruce Capital LLC grew its position in IDEXX Laboratories by 1.1% during the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares in the last quarter. Finally, Huntington National Bank grew its holdings in shares of IDEXX Laboratories by 0.5% during the second quarter. Huntington National Bank now owns 3,651 shares of the company’s stock valued at $1,958,000 after buying an additional 19 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by company insiders.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. Barclays started coverage on shares of IDEXX Laboratories in a research note on Monday. They issued an “overweight” rating and a $850.00 price target on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Monday. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Finally, UBS Group raised their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Trading Up 0.4%

IDXX stock opened at $701.83 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a market cap of $56.04 billion, a P/E ratio of 55.66, a PEG ratio of 4.17 and a beta of 1.67. The business has a fifty day moving average of $680.30 and a 200-day moving average of $617.20.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.